Article Text

Extended report
A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis
  1. Francis Berenbaum1,
  2. Joachim Grifka2,
  3. Sara Cazzaniga3,
  4. Massimo D'Amato3,
  5. Giampaolo Giacovelli3,
  6. Xavier Chevalier4,
  7. Francois Rannou5,
  8. Lucio C Rovati3,
  9. Emmanuel Maheu1
  1. 1Department of Rheumatology, AP-HP Saint-Antoine Hospital, Paris, France
  2. 2Department of Orthopaedics, University Hospital, Regensburg, Germany
  3. 3Department of Clinical Pharmacology, Rottapharm|Madaus, Monza, Italy
  4. 4Department of Rheumatology, AP-HP Henri Mondor Hospital, University Paris XII, Créteil, France
  5. 5Department of Rehabilitation, AP-HP Cochin Hospital, Paris-Descartes University, Paris, France
  1. Correspondence to Emmanuel Maheu, AP-HP Saint-Antoine Hospital, 184 rue du faubourg Saint-Antoine, 75012 Paris, France; emaheu{at}wanadoo.fr

Abstract

Objectives To compare the effects of an intermediate molecular weight (MW) intra-articular hyaluronic acid (HA) with a low MW product on knee osteoarthritis (OA) symptoms.

Methods Patients with symptomatic knee OA were enrolled inarandomised, controlled, double-blind, parallel-group, non-inferiority trial with the possibility to shift to superiority. Patients were randomised to GO-ON(MW 800–1500 kD, 25 mg/2.5 ml) or Hyalgan(MW 500–730 kD, 20 mg/2 ml) injected at 3-weekly intervals. The primary outcome was 6-month change in the WOMAC pain subscale (0–100 mm). Sample size was calculated on a non-inferiority margin of 9 mm, lower than the minimum perceptible clinical improvement. Secondary endpoints included OARSI-OMERACT responder rates

Results The intention-to-treat (ITT) and per-protocol (PP) populations consisted of 217 and 209 patients and 171 and 172 patients in the GO-ON and Hyalgan groups, respectively. ITT WOMAC pain of 47.5±1.0(SE) and 48.8±1.0 mm decreased by 22.9±1.4 mm with GO-ON and 18.4±1.5 mm with Hyalgan after 6 months. The primary analysis was conducted in the PP population followed by the ITT population.Mean (95% CI) differences in WOMAC pain change were 5.2 (0.9 to 9.6)mm and 4.5 (0.5 to 8.5)mm, respectively,favouring GO-ON, satisfying the claim for non-inferiority (lower limit>−9 mm) and for statistical superiority (95% CI all>0, p=0.021). Ahigher proportion of OARSI/OMERACT responders was observed with GO-ONthan with Hyalgan (73.3% vs58.4%, p=0.001). Both preparations were well tolerated.

Conclusions Treatment with 3-weekly injections of intermediate MW HA may be superior to low MW HA on knee OA symptoms over 6 months, with similar safety.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode

Statistics from Altmetric.com

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

    • Web Only Data - This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • Funding This was a trial conducted for regulatory purposes and therefore received full financial support from the sponsor Rottapharm|Madaus. Co-authors SC, MD, GG and LCR are scientists from the Department of Clinical Pharmacology of Rottapharm|Madaus and agreed individually to be listed as co-authors due to their involvement in the study; there was no other involvement of the sponsor as a corporate entity in the conduct of the study and in the manuscript submission process. Co-authors FB and JG were the study principal investigators and received research grants for this. Co-authors FB, XC, FR and EM received a reimbursement fee for their involvement in the steering committee of the study.

  • Competing interests Rottapharm|Madaus is the sponsor of the study and the manufacturer of one of the preparations tested in this study (GO-ON) and has this preparation on the market in different countries of the world. The full trial protocol, all study documents including completed case record forms and the complete statistical database are available from the sponsor's good clinical practice archives.

  • Ethics approval Ethics approval was provided by the Comité de Protection des Personnes, AP-HP St-Antoine Hospital, Paris and the ethics committee of Regensburg University and by all applicable local ethics committees.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.